Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 11Recruiting 5Active not recruiting 5Terminated 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 5OTHER 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Gynecologic 1

Conditions

Non Small Cell Lung Carcinoma NSCLC 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × CP protocol × Clear all
NCT02453282 2026-05-12

MYSTIC

AstraZeneca

Phase 3 Active not recruiting
1,118 enrolled 40 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

AstraZeneca

Phase 3 Active not recruiting
328 enrolled 23 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03737643 2025-01-29

DUO-O

AstraZeneca

Phase 3 Active not recruiting
1,407 enrolled 1 FDA
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡